Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.77

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $5.77.

Separately, HC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a report on Tuesday, January 7th.

CytomX Therapeutics Trading Down 5.2 %

CytomX Therapeutics stock traded down $0.05 during mid-day trading on Tuesday, hitting $0.84. The company had a trading volume of 1,080,240 shares, compared to its average volume of 1,332,181. The company has a market capitalization of $65.82 million, a price-to-earnings ratio of 4.95 and a beta of 1.07. The company's fifty day moving average is $1.05 and its 200-day moving average is $1.16. CytomX Therapeutics has a 12-month low of $0.81 and a 12-month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.16) by $0.23. The company had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same quarter last year, the business earned $0.04 earnings per share. As a group, sell-side analysts expect that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Hedge Funds Weigh In On CytomX Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC raised its holdings in CytomX Therapeutics by 17.3% in the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company's stock valued at $335,000 after acquiring an additional 41,949 shares during the last quarter. Geode Capital Management LLC grew its position in shares of CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company's stock valued at $948,000 after purchasing an additional 34,032 shares in the last quarter. XTX Topco Ltd increased its holdings in shares of CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company's stock valued at $74,000 after purchasing an additional 48,033 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company's stock worth $100,000 after buying an additional 40,309 shares in the last quarter. Finally, US Bancorp DE acquired a new position in CytomX Therapeutics during the third quarter worth $40,000. Hedge funds and other institutional investors own 67.77% of the company's stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.